glp-1-based treatments approved for weight loss 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ The GLP-1 Revolution Continues

We are currently evaluating claims involving the following diagnoses: Severe Gastroparesis (Stomach Paralysis) Ileus (Bowel Obstruction) Intraoperative Pulmonary Aspiration (Choking on stomach contents during surgery) Other Serious Gastrointestinal Injuries requiring ER visits or hospitalization

Vial Duration Calculator Calculate how many days a reconstituted vial will last based on your dosing protocol

The majority of organizations (76 percent) provide GLP-1 drug coverage for diabetesthe original intended use for drugs including Ozempicfar outpacing the percentage of those providing coverage for weight loss, according to a new survey of 200 employers out from the International Foundation of Employee Benefit Plans (IFEBP)

[PubMed: 6024164] 341